| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/EJHF.1434 |
| P698 | PubMed publication ID | 30884037 |
| P2093 | author name string | Hossein Ardehali | |
| Hsiang-Chun Chang | |||
| Kambiz Ghafourian | |||
| P2860 | cites work | Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones | Q33613458 |
| Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners | Q33700880 | ||
| High Output Cardiac Failure | Q33937390 | ||
| FGF23 induces left ventricular hypertrophy | Q34028891 | ||
| Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. | Q34041875 | ||
| Regulation of ferritin genes and protein | Q34126332 | ||
| Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects | Q34333986 | ||
| Systemic iron homeostasis | Q34378495 | ||
| Anemia of chronic disease. | Q34401570 | ||
| 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib | Q34677347 | ||
| The emerging role of the gut in chronic heart failure | Q34805115 | ||
| Iron homeostasis and the inflammatory response | Q35024676 | ||
| Soluble transferrin receptor for the evaluation of erythropoiesis and iron status | Q35067710 | ||
| A randomized trial of intravenous and oral iron in chronic kidney disease | Q36108862 | ||
| Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis | Q36354815 | ||
| When less is more: novel mechanisms of iron conservation | Q36483828 | ||
| Fallacies of last observation carried forward analyses | Q36669613 | ||
| Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives | Q36682182 | ||
| Assessing iron status: beyond serum ferritin and transferrin saturation | Q36910512 | ||
| Hepcidin and iron metabolism: from laboratory to clinical implications | Q37771565 | ||
| Intravenous iron in heart failure: beyond targeting anemia | Q37807903 | ||
| Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches | Q37883005 | ||
| Iron supplementation for the treatment of chronic heart failure and iron deficiency: systematic review and meta-analysis | Q37986258 | ||
| Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). | Q38031378 | ||
| Iron deficiency: an emerging therapeutic target in heart failure | Q38222610 | ||
| Iron metabolism in transplantation | Q38223148 | ||
| Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency | Q38374099 | ||
| Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial | Q38376716 | ||
| Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials | Q38715116 | ||
| Iron-induced hypophosphatemia: an emerging complication | Q38731872 | ||
| Disturbances in iron homeostasis result in accelerated rejection after experimental heart transplantation. | Q38857830 | ||
| Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic? | Q39409288 | ||
| Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study | Q41125350 | ||
| Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds | Q41282906 | ||
| Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions | Q42370571 | ||
| Ferric carboxymaltose in patients with heart failure and iron deficiency | Q43240282 | ||
| Getting to the "Heart" of Cardiac Disease by Decreasing Mitochondrial Iron. | Q43288665 | ||
| Deferoxamine reduces cold-ischemic renal injury in a syngeneic kidney transplant model | Q44663032 | ||
| The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure | Q44846324 | ||
| Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study | Q45136882 | ||
| Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia | Q46279772 | ||
| Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. | Q46645329 | ||
| Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial | Q46810797 | ||
| Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease | Q46909992 | ||
| Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency | Q46940287 | ||
| Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients. | Q47141724 | ||
| Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials | Q47243096 | ||
| 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure | Q47374177 | ||
| "Pumping Iron" to Improve Exercise Performance in Heart Failure: New Data and New Guidelines | Q47833055 | ||
| Iron in kidney and heart failure: from theory to practice | Q48306942 | ||
| Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure | Q48716818 | ||
| Repletion of Iron Stores With the Use of Oral Iron Supplementation in Patients With Systolic Heart Failure | Q48795904 | ||
| IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. | Q48955860 | ||
| Modern iron replacement therapy: clinical and pathophysiological insights | Q49351942 | ||
| Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients | Q49572149 | ||
| Sucrosomial® iron absorption studied by in vitro and ex-vivo models | Q50064172 | ||
| Iron-induced oxidative rat liver injury after non-heart-beating warm ischemia is mediated by tumor necrosis factor α and prevented by deferoxamine. | Q50695748 | ||
| On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. | Q50784793 | ||
| Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. | Q51298364 | ||
| Nutritional intake and oxidative stress in chronic heart failure | Q60432158 | ||
| IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000 | Q73566942 | ||
| Iron repletion in heart failure patients | Q83288258 | ||
| Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: a prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index | Q84661276 | ||
| Ironing out iron deficiency in heart failure | Q87892834 | ||
| 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society o | Q87967845 | ||
| Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency | Q88837294 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 703-714 | |
| P577 | publication date | 2019-03-18 | |
| P1433 | published in | European Journal of Heart Failure | Q5017954 |
| P1476 | title | Intravenous iron therapy in heart failure: a different perspective | |
| P478 | volume | 21 |
| Q101041624 | High Soluble Transferrin Receptor in Patients With Heart Failure: a Measure of Iron Deficiency And a Strong Predictor of Mortality |
| Q92214661 | Intravenous iron supplementation is state of the art therapy in patients with heart failure and iron deficiency |
| Q100516700 | Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial |
| Q104802877 | Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia |
Search more.